Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Bauernhofer, T; Pichler, M; Wieckowski, E; Stanson, J; Aigelsreiter, A; Griesbacher, A; Groselj-Strele, A; Linecker, A; Samonigg, H; Langner, C; Whiteside, TL.
Prolactin receptor is a negative prognostic factor in patients with squamous cell carcinoma of the head and neck.
Br J Cancer. 2011; 104(10):1641-1648
Doi: 10.1038/bjc.2011.131
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Bauernhofer Thomas
- Co-Autor*innen der Med Uni Graz
- Aigelsreiter Ariane
- Griesbacher Antonia
- Groselj-Strele Andrea
- Langner Cord
- Linecker Alexander
- Pichler Martin
- Samonigg Hellmut
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: The influence of human prolactin (hPRL) on the development of breast and other types of cancer is well established. Little information, however, exists on the effects of hPRL on squamous cell carcinomas of the head and neck (SCCHNs). METHODS: In this study, we evaluated prolactin receptor (PRLR) expression in SCCHN cell lines and assessed by immunohistochemistry the expression in 89 patients with SCCHNs. The PRLR expression was correlated with clinicopathological characteristics as well as clinical outcome. The effect of hPRL treatment on tumour cell growth was evaluated in vitro. RESULTS: Immunoreactivity for PRLR was observed in 85 out of 89 (95%) tumours. Multivariate COX regression analysis confirmed high levels of PRLR expression (>25% of tumour cells) to be an independent prognostic factor with respect to overall survival (HR = 3.70, 95% CI: 1.14-12.01; P = 0.029) and disease-free survival (P = 0.017). Growth of PRLR-positive cancer cells increased in response to hPRL treatment. CONCLUSION: Our data indicate that hPRL is an important growth factor for SCCHN. Because of PRLR expression in a vast majority of tumour specimens and its negative impact on overall survival, the receptor represents a novel prognosticator and a promising drug target for patients with SCCHNs. British Journal of Cancer (2011) 104, 1641-1648. doi: 10.1038/bjc.2011.131 www.bjcancer.com Published online 19 April 2011 (C) 2011 Cancer Research UK
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Aged, 80 and over -
- Carcinoma - genetics
- Carcinoma, Squamous Cell -
- Cell Line, Tumor -
- Disease-Free Survival -
- Female -
- Head and Neck Neoplasms - genetics
- Humans -
- Immunohistochemistry -
- Male -
- Middle Aged -
- Neoplasm Recurrence, Local - genetics
- Neoplasm Staging -
- Neoplasms, Squamous Cell - genetics
- Prognosis -
- Prolactin - pharmacology
- Receptors, Prolactin - biosynthesis
- Find related publications in this database (Keywords)
- prolactin receptor
- head and neck cancer
- prognosis
- growth factor
- proliferation